Guardant Health (GH) Set to Announce Quarterly Earnings on Wednesday

Guardant Health (NASDAQ:GH - Get Free Report) is scheduled to be releasing its earnings data after the market closes on Wednesday, November 6th. Analysts expect Guardant Health to post earnings of ($0.55) per share for the quarter. Guardant Health has set its FY 2024 guidance at EPS.Persons that wish to register for the company's conference call can do so using this link.

Guardant Health (NASDAQ:GH - Get Free Report) last released its earnings results on Wednesday, August 7th. The company reported ($0.84) EPS for the quarter, missing analysts' consensus estimates of ($0.74) by ($0.10). Guardant Health had a negative return on equity of 418.21% and a negative net margin of 76.23%. The company had revenue of $177.24 million during the quarter, compared to analysts' expectations of $162.59 million. During the same period in the prior year, the company posted ($0.67) earnings per share. The company's revenue was up 29.2% on a year-over-year basis. On average, analysts expect Guardant Health to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Guardant Health Stock Up 6.0 %

Shares of NASDAQ:GH traded up $1.31 during trading on Wednesday, reaching $23.10. 1,428,413 shares of the stock traded hands, compared to its average volume of 2,039,195. The stock has a 50-day moving average of $23.49 and a two-hundred day moving average of $25.66. The company has a debt-to-equity ratio of 16.70, a quick ratio of 6.07 and a current ratio of 6.40. Guardant Health has a 52-week low of $15.81 and a 52-week high of $37.04. The stock has a market cap of $2.83 billion, a P/E ratio of -5.97 and a beta of 1.11.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on GH shares. Leerink Partners lowered their price target on Guardant Health from $60.00 to $50.00 and set an "outperform" rating on the stock in a report on Thursday, October 17th. Bank of America boosted their price target on Guardant Health from $28.00 to $40.00 and gave the company a "buy" rating in a research note on Thursday, July 18th. UBS Group increased their price objective on shares of Guardant Health from $32.00 to $40.00 and gave the stock a "buy" rating in a research note on Wednesday, August 21st. BTIG Research raised their price objective on shares of Guardant Health from $45.00 to $50.00 and gave the stock a "buy" rating in a report on Tuesday, July 30th. Finally, Craig Hallum upped their target price on shares of Guardant Health from $28.00 to $37.00 and gave the company a "buy" rating in a report on Thursday, August 8th. One analyst has rated the stock with a hold rating and seventeen have given a buy rating to the company's stock. Based on data from MarketBeat, Guardant Health currently has an average rating of "Moderate Buy" and an average target price of $40.00.

About Guardant Health

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.